Search the database for deliberate release of GM medicinal products
Displaying 1 - 4 of 4
|EU record number
|Company / Sponsor
|Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors
|SCS Boehringer Ingelheim Comm.V
|BI 1831169 is a recombinant live-attenuated Vesicular Stomatitis Virus (rVSV), modified to replace the VSV-G glycoprotein with the Lymphocytic Choriomeningitis Virus glycoprotein in order to minimize the potential of neurotoxicity for humans and skin disease in animals.
|Only notified under the "contained use" procedure. Dossier submitted on 02/12/2019.
|A multicentre, open-label, single ascending dose, dose-ranging, phase I/Iia study to evaluate the safety and tolerability of an autologous antigen-specific chimeric antigen receptor T regulatory cell therapy (TX200-TR101) in living donor renal transplant
|chimeric antigen receptor specific to the donor HLA A*2
|Only notified under the "contained use" procedure. Dossier submitted on 07/04/2017.
|Phase 1 clinical trial evaluation of two genetically modified vaccines against poliovirus
|Genetic modifications of the nOPV2 vaccine candidates aimed at stabilizing the genetic sequence against reversion compared to the Sabin-2 strain, nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3), nOPV2 candidate 2 (S2/S15domV/CpG40)
|Only notified under the "contained use" procedure. Dossier submitted on 24/10/1996.
|Prospective, open-label, parallel-group, randomized, multicenter trial comparing the efficacy of surgery, radiation, and injection of murine cells producing herpes simplex thymidine kinase vector followed by intravenous ganciclovir against the efficacy of
|Genetic therapy, Inc., Sandoz Pharma, Ltd
|Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)